Between billion-dollar IPOs and big-name exclusive partnerships, it's a good time to be a giant in the CRO world. However, all the recent consolidation has made it harder for mid-size outfits to compete, as medium-capped players lack the capacity to challenge heavyweights and don't offer the kind of niche services that keep small CROs afloat.
Shares of Icon and Parexel slipped a bit yesterday as a crowd of analysts gathered around to criticize the CROs on the downside of a new wave of strategic relationships with Big Pharma companies.
The big CRO Parexel outlined plans to restructure its early-stage research efforts last month, offering a big-picture effort to cut back by 30 percent. Now the axe is falling on all nine of its
As Pfizer hatchets billions of dollars from its R&D budget it's turning to two CROs as preferred providers for outsourcing its clinical trial work. In separate releases Parexel and Icon both
Shares of Parexel International took a beating this morning after the CRO noted a shortfall in early-phase research work that is triggering a restructuring in that segment of its drug research
Merck is boosting its biologics unit in a deal with Parexel. The CRO will provide its clinical development services for Merck BioVenture, including access to regulatory strategy and clinical
Global contract researcher PAREXEL has stepped into the cold chain business. The company has unveiled an integrated study-drug transport system for temperature monitoring based on radio-frequency
After flirting with the idea of making a competing offer for ClinPhone, Quintiles Transnational has backed away from the table,
CRO Parexel has made a $182 million bid for U.K.-based ClinPhone, but it may be facing competition from Quintiles, the world's largest private CRO. ClinPhone helps drug developers select trial